Eisai's Halaven gains positive CHMP opinion for advanced liposarcoma

Eisai's Halaven has received a positive opinion from the Europe's key medicines approval committee for its use in unresectable advanced or metastatic liposarcoma following the results from phase 3 ... read more

Crucial high seas treaty stuck over sharing of genetic resources

Delegates deplore ‘insensitivity and privilege’ of developed nations as negotiators disagree over who should benefit from marine discoveries ... read more

Halaven Vial Side Effects by Likelihood and Severity

low amount of calcium in the blood low amount of potassium in the blood a significant drop in a certain type of white blood cell called a neutrophil ... read more

German pricing rules hit Eisai's Halaven

Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit ... read more

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results ... read more

Managing Sacituzumab AEs and Looking Forward to Next-Line TNBC Therapy

RITA MAITY MUKHERJEE, MD: I generally use sacituzumab, but if not, then eribulin [Halaven] is an alternative. If the patient is elderly or has more frailties, that is something I would use. MUKHERJEE: ... read more

Related Blogs:


Real Time RSS Feeds | Disclaimer | Contact Us